Emmyon, Inc.

  • About Us
    • Overview
    • People
  • Technology
    • Platform
    • Natural Compounds
    • Novel Compounds
    • Patents
    • Publications
  • Commercial Applications
    • Human Nutrition
    • Companion Animal Nutrition
    • Production Animal Nutrition
    • Pharmaceuticals
  • News
  • Contact
Home / Archives for redilson

Emmyon scientists discover new molecular mechanisms of skeletal muscle atrophy

Apr 8, 2015 By redilson

January 15, 2015, Iowa City, IA. – Emmyon scientists Chris Adams and Scott Ebert have co-authored two new papers describing novel molecular mechanisms of skeletal muscle atrophy. The research was performed in the Adams laboratory at the University of Iowa.

The first paper identifies two proteins (p53 and ATF4) that work together to cause muscle atrophy when muscles are immobilized (American Journal of Physiology – Endocrinology and Metabolism, volume 307, pages E245-261).

The second paper identifies a protein (spermine oxidase) that helps to protect muscle from atrophy (American Journal of Physiology – Endocrinology and Metabolism, volume 308, pages E144-158).

Understanding basic mechanisms of skeletal muscle atrophy helps us find new ways to combat it.

Filed Under: News

Emmyon receives Phase I STTR award from the National Institute on Aging

Jul 8, 2014 By redilson

July 8, 2014, Coralville, IA. – Emmyon is pleased to announce that it has received a new Phase I STTR award from the National Institute on Aging.  The funding will support research to discover and develop pharmaceutical compounds that improve muscle mass, function and metabolism.

Filed Under: News

Emmyon research featured in Chemical and Engineering News

Jun 9, 2014 By redilson

May 5, 2014, Washington D.C. – Emmyon research was featured today in Chemical and Engineering News, a publication of the American Chemical Society. The article, “A Natural Green Boost for Muscles,” may be found here.

cen-image
Click image to view

Filed Under: News

Emmyon scientists discover natural small molecule inhibitor of skeletal muscle atrophy

Apr 23, 2014 By redilson

April 9, 2014, Coralville, IA. – Emmyon scientists Christopher Adams and Scott Ebert published a new paper today describing the discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy. The paper, published in The Journal of Biological Chemistry, may be found here.

Filed Under: News

Emmyon completes licensing agreement with the University of Iowa

Apr 23, 2014 By redilson

April 8, 2014, Coralville, IA. – Emmyon is pleased to announce that it has completed a licensing agreement with the University of Iowa. The agreement provides Emmyon an exclusive license to patent rights for a portfolio of small molecules. These small molecules, which include ursolic acid and tomatidine, increase skeletal muscle mass, strength and exercise capacity, and decrease skeletal muscle atrophy and obesity.

Filed Under: News

Emmyon founder presents at NIH-sponsored symposium on systems-based drug discovery

Mar 26, 2014 By redilson

November 19, 2013, Cambridge, MA. – Emmyon’s Founder and President, Dr. Christopher Adams, presented a plenary lecture, “Discovering small-molecule inhibitors of skeletal muscle atrophy,“ at the Library of Integrated Network-Based Cellular Signatures (LINCS) Symposium.  The Symposium was sponsored by the National Institutes of Health and held at the Broad Institute of MIT and Harvard.  Dr. Adams’s lecture may be viewed and downloaded via the Broad Institute site on iTunesU.  Additional information may be found here (http://www.broadinstitute.org/icmap/lincs_symposium/)

symposium

 

Filed Under: News

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Emmyon logo
emmyon@emmyon.com LinkedIn logo
Emmyon® is a registed trademark of Emmyon, Inc.
© Copyright 2018 - 2026 Emmyon, Inc. All Rights Reserved.